I don’t have enough detail to give a single reliable figure for “the manufacturing plant cost” of canagliflozin (Invokana), because costs vary hugely by scope (API vs finished tablets), capacity, location, and whether it’s a brand-new greenfield facility or an upgraded/expanded plant.
That said, here’s what I can tell you:
What’s typically involved (why cost estimates are hard)
Canagliflozin production involves at least:
- API (active ingredient) manufacturing plants (often the most capital-intensive and regulated)
- Formulation/finished-dose (tablets/capsules) facilities
- Quality control, validation labs, waste treatment, clean utilities, etc.
Typical order-of-magnitude costs (for context)
For modern pharmaceutical facilities, ballpark ranges commonly cited in industry/finance references are roughly:
- Formulation/finished-dose plants: often tens to a few hundred million USD
- API plants (API manufacturing units) for complex molecules: often hundreds of millions to >$1B USD depending on capacity and complexity
A crucial point
Public sources rarely disclose “the” exact Invokana/canagliflozin plant construction cost for a specific site, especially for proprietary manufacturing and multiple supplier networks.
Quick questions so I can narrow it down
- Do you mean the cost for an API plant or a finished-dose (tablet) plant?
- Which country/site are you asking about (or which company / partner)?
- Are you looking for a new plant build cost, or total investment/expansion capex?
If you share any of those details (even just the site/city or the company running it), I can try to find the most relevant publicly reported capex/estimate and give you a tighter number.